3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gastrointestinal
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Medullary
3
Thoracic Neoplasms
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Neoplasms, Nerve Tissue
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lung Neoplasms
2
Lung Diseases
2
Head and Neck Neoplasms
2
Carcinoma, Bronchogenic
2
Carcinoma
2
Adenocarcinoma
2
Thyroid Neoplasms
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Solid Tumors
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors
1
Neoplasms, Glandular and Epithelial
1
Multiple Endocrine Neoplasia Type 2a
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Endocrine System Diseases
1
Endocrine Gland Neoplasms
1
Interventions
pembrolizumab
3
napabucasin
3
Bevacizumab
3
entinostat
2
Paclitaxel
2
Ocoxin
2
Leucovorin
2
Irinotecan
2
Immunotherapy
2
Gemcitabine
2
Fluorouracil
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
vorasidenib
1
sipuleucel-T
1
pralsetinib
1
palbociclib
1
luprolide acetate gel depot
1
linifanib
1
lenvatinib
1
interferon gamma-1b
1
ficlatuzumab
1
durvalumab
1
catumaxomab
1
Vaccines
1
VB6-845 fusion protein
1
Taxes
1
Sorafenib
1
Pemetrexed
1
Papillomavirus Vaccines
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasms, Glandular and Epithelial
×
pralsetinib
×
Clear all
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA